Introduction {#s1}
============

Cancer has become a major threat to public health worldwide ([@B1]). In 2018, there is a predicted 1,735,350 new cancer cases, which are equivalent to over 4,700 new cancer diagnoses each day in the United States, which correspond to an expected 609,640 cancer deaths ([@B2]). In addition, cancer has become the leading cause of death in China ([@B3]). Therefore, there is an urgent need to investigate cancer, identify relevant biomarkers, and develop strategies for active prevention and early diagnosis and treatment. Cancer is well-established to be the result of a combination of genetic and environmental factors. In the last few decades, extensive experimental and epidemiological findings demonstrated the close association between genetic alterations and tumor risk ([@B4]). Single nucleotide polymorphisms (SNPs), the most common form of gene alteration in the human genome, refers to single-nucleotide variations with distribution frequencies that are \>1% in the population.

Phospholipase C epsilon1 (*PLCE1*), which is located on chromosome 10q23, is a member of the phospholipase C protein family ([@B5]). In 2010, the results of genome-wide association studies indicated that *PLCE1* is associated with cancer risk ([@B6], [@B7]). Since then, multiple researchers investigated the relationship between *PLCE1* polymorphisms and cancer risk. Cui et al. ([@B8]) explored the association between *PLCE1* polymorphisms and risk for esophageal squamous cell carcinoma. Li ([@B9]), Zhang ([@B10]) and other authors investigated the relationship between *PLCE1* polymorphisms and colorectal cancer risk. Yuan ([@B11]), Malik ([@B12]) and other authors investigated the association between *PLCE1* polymorphisms and gastric carcinoma risk. Sharma ([@B13]) and other authors showed that *PLCE1* polymorphisms were associated with susceptibility to developing gall bladder cancer. Among all studies that investigated *PLCE1* polymorphisms and cancer susceptibility, the SNPs rs2274223, rs3765524, rs753724, rs11187842, and rs7922612 were five of the most extensively studied polymorphic loci. However, we noted significant differences in the results, sample size, race, or selection of controls among the different studies. In addition, the latest meta-analysis on the relationship between the rs2274223 polymorphism and the overall cancer risk was published in 2015 ([@B14]). Furthermore, to the best of our knowledge, no studies conducted meta-analysis of the association of rs3765524, rs753724, rs11187842, and rs7922612 polymorphisms with overall cancer risk. Therefore, in the present study, we summarized all currently qualified case-control studies to obtain a more accurate understanding of the relationship between the *PLCE1* polymorphism rs2274223 and overall cancer risk \[([@B15]) studies were added to the current meta-analysis from the meta-analysis published in 2015 ([@B14])\]. And we firstly performed a meta-analysis of the association between the rs3765524, rs753724, rs11187842, and rs7922612 polymorphisms and cancer risk in the overall population.

Methods {#s2}
=======

Literature Search
-----------------

We carried a comprehensive search strategy to retrieve qualified publications from PubMed and Web of Science until 19 March 2018. The search queries comprised a combination of the Medical Subject Headings (MeSH) and the following keywords: (rs2274223 OR rs3765524 OR rs753724 OR rs11187842 OR rs7922612) OR (*PLCE1* OR PLCE OR PPLC OR NPHS3) and (cancer OR tumor OR carcinoma OR neoplasm OR malignancy). In addition, we searched literatures from Medline, EMbase, and Scopus, as complementary data. The references of qualified articles or other reviews were additionally searched. For publications with no available original data, we contacted the authors to ensure that data from all qualified literatures were included in the current meta-analysis. The authors of three out of six publications responded.

Inclusion Criteria and Exclusion Criteria
-----------------------------------------

The inclusion criteria for qualified literatures were as follows: (a) The studies evaluated the associations between *PLCE1* polymorphisms (rs2274223 or rs3765524 or rs753724 or rs11187842 or rs7922612) and cancer risk. (b) The study had available genotyping data required for the calculation of the odds ratios (ORs) with 95% confidence intervals (95% CIs). (c) The studies were case-control studies. (d) Studies were complete original articles. Exclusion criteria of qualified literatures were as follows: (a) Articles did not estimate the relationships between the *PLCE1* (rs2274223, rs3765524, rs753724, rs11187842, or rs7922612) polymorphisms and cancer susceptibility. (b) The article was a repeated publication. (d) Primary data were missing and were not obtained after contacting the authors. (e) The subjects were not human. Two researchers independently retrieved the literature. In the case of different views in the selected literature, the two researchers discussed to reach an agreement or the decision was made by an independent researcher (Xuelian Li).

Reporting Items
---------------

Two investigators independently gathered data from each selected article, including the first author, year, country, ethnicity, tumor type, genotyping methods, the source of control, number of cases and controls, and the *P*-values of the HWE test of the controls. In the case of different views, the two researchers reached an agreement through discussion.

Quality Score Assessment
------------------------

All qualified literatures were individually assessed by two researchers based on the Newcastle-Ottawa scale (NOS) ([@B16]). The assessment results indicated that all selected literatures were of relatively high quality (all NOS scores were ≥6). In addition, the two researchers assessed the quality of the studies using the STREGA (strengthening report of genetic association studies) quality score system ([@B15]). All STREGA scores were \>12, which indicated that the quality of the studies was moderate-high or high.

Statistical Analysis
--------------------

Hardy-Weinberg equilibrium (HWE) was examined by performing a Chi-square test in the controls. Heterogeneity was evaluated by conducting *Q*-test and *I*^2^-test. In addition, the pooled ORs with 95% CIs were calculated based on the random effects model when heterogeneity was significant (*I*^2^ \> 50%) ([@B17]). Otherwise, pooled ORs with 95% CIs were calculated according to the fixed-effects model ([@B18]). The pooled ORs with 95% CIs were used to evaluate relationships between the *PLCE1* polymorphisms (rs2274223, rs3765524, rs753724, rs11187842, and rs7922612) and cancer susceptibility. To investigate the potential sources of heterogeneity across different studies, stratification and meta-regression analyses were conducted. Sensitivity analyses were carried out to evaluate the stability of the results. The effect of publication bias was evaluated using Begg\'s funnel plot ([@B19]) and Egger\'s test ([@B20]). All the above analyses were performed using Stata 11 software. *P* \< 0.05 was considered statistically significant.

Results {#s3}
=======

Study Characteristics
---------------------

A total of 32 literatures were eventually included based on the above described comprehensive search strategy. The workflow of the enrollment in the meta-analysis is presented in Figure [1](#F1){ref-type="fig"}. A total of 54 case-control studies comprising 17,955 cases and 20,400 controls were included in the 32 publications. Five target SNPs were investigated in the current meta-analysis. The main characteristics of the 54 case-control studies and the genotype distribution information of the five polymorphisms are summarized in Table [1](#T1){ref-type="table"}. The rs2274223, rs3765524, rs753724, and rs11187842, rs7922612 polymorphisms were involved in 35 ([@B8], [@B9], [@B12], [@B21]--[@B45]), eight ([@B8], [@B9], [@B12], [@B34], [@B38], [@B45]--[@B47]), four ([@B8]--[@B10], [@B48]), four ([@B8]--[@B48]), and three studies ([@B12], [@B31], [@B38]), respectively. The different cancer types investigated included gastric cancer, head and neck cancer, colorectal cancer, esophageal cancer, gall bladder cancer, and lung cancer. Of all case-control studies, only genotype frequencies of three studies among the controls were not consistent with HWE ([@B45], [@B46]). A total of 36 studies involved Asians; 16 studies involved Caucasians; one study involved Africans; and one study involved individuals of mixed ancestry. Meanwhile, 35 studies were hospital-based, and 17 studies were population-based. All studies were case-control studies.

![The workflow of the enrollment \[Literatures sources: PubMed *n* = 112, Web of Science *n* = 201, other literatures were supplemented by Medline, EMbase, and Scopus, as well as the references of qualified literatures or other reviews; previous literature^\*^ ([@B13])\].](fonc-08-00613-g0001){#F1}

###### 

Characteristics of studies.

  **First author**             **Year**   **Country**            **Ethnicity**   **Cancer type**   **Source of control**   **Genotyping methods**        **Cases (*****n*****)**   **Controls(*****n*****)**   **HWE (*P*)**                      
  ---------------------------- ---------- ---------------------- --------------- ----------------- ----------------------- ----------------------------- ------------------------- --------------------------- --------------- ------ ----- ----- --------
  **rs2274223**                                                                                                                                                                                                                                   
  Zhang et al. ([@B21])        2011       China                  Asian           GC                PB                      TaqMan                        867                       664                         134             1122   643   83    \>0.05
  Ma et al. ([@B22])           2011       USA                    Caucasian       HNC               HB                      TaqMan                        477                       506                         114             504    474   111   \>0.05
  Li et al. ([@B9])            2012       China                  Asian           CRC               HB                      MassArray                     155                       71                          5               180    92    20    \>0.05
  Zhou et al. ([@B23])         2012       China                  Asian           EC                PB                      PCR                           248                       227                         42              291    191   280   \>0.05
  Gu et al. ([@B24])           2012       China                  Asian           EC                HB                      MassArray                     202                       147                         30              233    119   19    \>0.05
  Hu et al. ([@B25])           2012       China                  Asian           EC                HB                      TaqMan                        594                       400                         67              754    399   58    \>0.05
  Bye et al. ([@B26])          2012       South African          African         EC                Mixed                   TaqMan                        140                       208                         70              302    411   137   \>0.05
  Bye et al. ([@B26])          2012       South African          Mixed           EC                HB                      TaqMan                        78                        130                         46              310    408   139   \>0.05
  Palmer et al. ([@B27])       2012       Poland                 Caucasian       GC                PB                      TaqMan                        107                       138                         44              154    166   56    \>0.05
  Palmer et al. ([@B27])       2012       USA                    Caucasian       GC                PB                      TaqMan                        132                       150                         24              86     107   17    \>0.05
  Palmer et al. ([@B27])       2012       USA                    Caucasian       EC                PB                      TaqMan                        30                        18                          4               86     107   17    \>0.05
  Palmer et al. ([@B27])       2012       USA                    Caucasian       EC                PB                      TaqMan                        44                        50                          13              86     107   17    \>0.05
  Wang et al. ([@B28])         2012       China                  Asian           GC                PB                      TaqMan                        600                       399                         60              791    390   59    \>0.05
  Cui et al. ([@B8])           2013       China                  Asian           EC                HB                      MassArray                     108                       93                          21              193    121   12    \>0.05
  Yuan et al. ([@B29])         2013       China                  Asian           HNC               PB                      TaqMan                        301                       170                         30              547    300   32    \>0.05
  Duan et al. ([@B30])         2013       China                  Asian           EC                PB                      PCR                           193                       150                         38              281    123   16    \>0.05
  Sharma et al. ([@B31])       2013       North Indian           Caucasian       GBC               HB                      PCR                           174                       229                         13              111    98    16    \>0.05
  Dura et al. ([@B32])         2013       Netherlands            Caucasian       EC                PB                      PCR                           42                        38                          6               279    247   54    \>0.05
  Dura et al. ([@B32])         2013       Netherlands            Caucasian       EC                PB                      PCR                           118                       116                         24              279    247   54    \>0.05
  Li et al. ([@B33])           2013       China                  Asian           GC                HB                      TaqMan                        197                       122                         16              217    109   8     \>0.05
  Chen et al. ([@B34])         2013       China                  Asian           EC                PB                      MALDI-TOF MS                  97                        84                          19              178    111   11    \>0.05
  Yang et al. ([@B35])         2014       China                  Asian           EC                HB                      TaqMan                        172                       122                         19              209    96    9     \>0.05
  Malik et al. ([@B12])        2014       Kashmir                Asian           GC                HB                      PCR                           54                        45                          9               100    78    17    \>0.05
  Piao et al. ([@B36])         2014       Korea                  Asian           EC                PB                      PCR                           153                       140                         29              909    684   107   \>0.05
  Kupcinskas et al. ([@B37])   2014       Lithuania and Latvia   Caucasian       GC                HB                      PCR                           94                        126                         30              91     116   34    \>0.05
  Umar et al. ([@B38])         2014       India                  Caucasian       EC                HB                      PCR                           162                       120                         11              168    127   19    \>0.05
  Wang et al. ([@B39])         2014       China                  Asian           CRC               HB                      TaqMan                        228                       161                         28              269    128   19    \>0.05
  Song et al. ([@B40])         2014       Korea                  Asian           GC                PB                      HRM                           1818                      1197                        230             909    684   107   \>0.05
  Kupcinskas et al. ([@B41])   2015       Lithuania and Latvia   Caucasian       CRC               HB                      TaqMan                        77                        91                          24              147    173   56    \>0.05
  Jia et al. ([@B42])          2015       China                  Asian           EC                HB                      MassArray                     194                       140                         24              190    104   11    \>0.05
  Sun et al. ([@B43])          2015       China                  Asian           GC                PB                      PCR                           405                       254                         33              514    226   34    \>0.05
  Dong et al. ([@B44])         2015       China                  Asian           LC                HB                      iMLDR and direct sequencing   106                       46                          7               106    73    7     \>0.05
  Dong et al. ([@B44])         2015       China                  Asian           GC                HB                      iMLDR and direct sequencing   93                        56                          18              106    73    7     \>0.05
  Dong et al. ([@B44])         2015       China                  Asian           EC                HB                      iMLDR and direct sequencing   65                        39                          5               106    73    7     \>0.05
  Ezgi et al. ([@B45])         2016       Turkey                 Caucasian       CRC               HB                      PCR                           142                       48                          10              176    54    0     \<0.05
  **Rs3765524**                                                                                                                                                                                                                                   
  Li et al. ([@B9] \]          2012       China                  Asian           CRC               HB                      MassArray                     156                       70                          5               180    92    20    \>0.05
  Chen et al. ([@B34])         2013       China                  Asian           EC                PB                      MALDI-TOF MS                  108                       78                          14              176    108   16    \>0.05
  Cui et al. ([@B8])           2013       China                  Asian           EC                HB                      MassArray                     120                       87                          15              191    118   17    \>0.05
  Umar et al. ([@B38])         2014       India                  Caucasian       EC                HB                      PCR                           167                       113                         13              177    125   12    \>0.05
  Malik et al. ([@B12])        2014       Kashmir                Asian           GC                HB                      PCR                           58                        42                          8               109    74    12    \>0.05
  Mou et al. ([@B46])          2015       China                  Asian           GC                NA                      Universal tagged arrays       104                       64                          23              82     29    17    \<0.05
  Ezgi et al. ([@B45])         2016       Turkey                 Caucasian       CRC               HB                      PCR                           78                        112                         10              84     108   18    \<0.05
  Qu et al. ([@B47])           2017       China                  Asian           EC                PB                      PCR                           362                       169                         19              385    150   15    \>0.05
  **rs753724**                                                                                                                                                                                                                                    
  Li et al. ([@B9] \]          2012       China                  Asian           CRC               HB                      MassArray                     169                       57                          5               203    76    13    \>0.05
  Yuan et al. ([@B48])         2012       China                  Asian           GC                HB                      MassArray                     196                       80                          3               225    63    8     \>0.05
  Cui et al. ([@B8])           2013       China                  Asian           EC                HB                      MassArray                     133                       85                          4               246    77    3     \>0.05
  Zhang et al. ([@B10])        2015       China                  Asian           CRC               HB                      MassArray                     194                       66                          16              296    79    9     \>0.05
  **rs11187842**                                                                                                                                                                                                                                  
  Yuan et al. ([@B48] \]       2012       China                  Asian           GC                HB                      MassArray                     196                       80                          3               225    63    8     \>0.05
  Li et al. ([@B9])            2012       China                  Asian           CRC               HB                      MassArray                     169                       57                          5               203    76    13    \>0.05
  Cui et al. ([@B8])           2013       China                  Asian           EC                HB                      MassArray                     151                       68                          3               253    71    2     \>0.05
  Zhang et al. ([@B10])        2015       China                  Asian           CRC               HB                      MassArray                     174                       42                          14              279    76    8     \>0.05
  **rs7922612**                                                                                                                                                                                                                                   
  Sharma et al. ([@B31] \]     2013       North Indian           Caucasian       GBC               HB                      PCR                           67                        234                         115             24     122   79    \>0.05
  Malik et al. ([@B12])        2014       Kashmir                Asian           GC                HB                      PCR                           47                        47                          14              90     85    20    \>0.05
  Umar et al. ([@B38])         2014       India                  Caucasian       EC                HB                      PCR                           133                       132                         28              134    153   27    \>0.05

*GC, Gastric cancer; HNC, Head and neck cancer; CRC, Colorectal cancer; EC, Esophageal cancer; GBC, Gallbladder cancer; LC, Lung cancer; HB, Hospital-based; PB, Population-based; NA, Not available; AA AB BB: AA AG GG for rs2274223, CC CT TT for rs3765524, GG GT TT for rs753724, CC CT TT for rs11187842, CC CT TT for rs7922612*.

Meta-Analysis of the Relationship Between the *PLCE1* rs2274223 Polymorphism and Cancer Risk
--------------------------------------------------------------------------------------------

A total of 35 qualified case-control studies were included in this meta-analysis, which assessed the relationship between the *PLCE1* rs2274223 polymorphism and cancer susceptibility. We evaluated heterogeneity and selected the random effects model or the fixed-effects model based on the results of *Q*-test and *I*^2^-values. Results of the meta-analysis of the relationship between the *PLCE1* rs2274223 polymorphism and cancer risk are shown in Table [2](#T2){ref-type="table"} and Figure [2](#F2){ref-type="fig"}. Results showed a correlation between the rs2274223 polymorphism with significantly increased overall cancer susceptibility in all genetic models \[AG vs. AA: OR 1.168, 95% CI 1.084--1.259 (*P* \< 0.001); GG vs. AA: OR 1.351, 95% CI 1.163--1.570 (*P* \< 0.001); AG+GG vs. AA: OR 1.193, 95% CI 1.103--1.290 (*P* \< 0.001); GG vs. AA+AG: OR 1.262, 95% CI 1.102--1.446 (*P* = 0.001); G vs. A: OR 1.163, 95% CI 1.089--1.242 (*P* \< 0.001)\]. To further study the association between rs2274223 polymorphism and cancer risk, we carried out stratified analyses according to cancer type, ethnicity, the source of control, genotyping methods, and HWE. The results of subgroup analyses are also shown in Table [2](#T2){ref-type="table"}. Results according to the cancer type indicated that the rs2274223 polymorphism was associated with a higher risk of gastric cancer in four genetic models \[GG vs. AA: OR 1.317, 95% CI 1.041--1.667 (*P* = 0.022); AG+GG vs. AA: OR 1.163, 95% CI 1.002--1.350 (*P* = 0.047); GG vs. AA+AG: OR 1.271, 95% CI 1.114--1.449 (*P* \< 0.001); G vs. A: OR 1.144, 95% CI 1.018--1.286 (*P* = 0.023)\]. Meanwhile, the rs2274223 polymorphism was related to a significantly increased risk of esophageal cancer in all genetic models \[AG vs. AA: OR 1.247, 95% CI 1.157--1.344 (*P* \< 0.001); GG vs. AA: OR 1.542, 95% CI 1.247--1.907 (*P* \< 0.001); AG+GG vs. AA: OR 1.266, 95% CI 1.133--1.415 (*P* \< 0.001); GG vs. AA+AG: OR 1.356, 95% CI 1.192--1.544 (*P* \< 0.001); G vs. A: OR 1.226, 95% CI 1.112--1.351 (*P* \< 0.001)\]. However, we found no statistically significant associations between the rs2274223 polymorphism and risks of head and neck cancer and colorectal cancer. The results of subgroup analyses according to ethnicity indicated that the rs2274223 polymorphism increased cancer susceptibility in Asians \[AG vs. AA: OR 1.221, 95% CI 1.102--1.352 (*P* \< 0.001); GG vs. AA: OR 1.665, 95% CI 1.381--2.006 (*P* \< 0.001); AG+GG vs. AA: OR 1.270, 95% CI 1.142--1.412 (*P* \< 0.001); GG vs. AA+AG: OR 1.465, 95% CI 1.316--1.632 (*P* \< 0.001); G vs. A: OR 1.251, 95% CI 1.145--1.366 (*P* \< 0.001)\]. However, the association between rs2274223 polymorphism and cancer risk was not identified in Caucasians. The results of subgroup analyses based on the source of control showed that the rs2274223 polymorphism was associated with significantly increased risk of tumor in hospital-based subgroup \[AG vs. AA: OR 1.188, 95% CI 1.106--1.277 (*P* \< 0.001); GG vs. AA: OR 1.289, 95% CI 1.009--1.647 (*P* = 0.042); AG+GG vs. AA: OR 1.206, 95% CI 1.126--1.291 (*P* \< 0.001); G vs. A: OR 1.150, 95% CI 1.050--1.259 (*P* = 0.003)\]. Meanwhile, the statistically significant relationship between the rs2274223 polymorphism and cancer susceptibility was also detected in the population-based subgroup \[AG vs. AA: OR 1.169, 95% CI 1.028--1.329 (*P* = 0.017); GG vs. AA: OR 1.448, 95% CI 1.184--1.770 (*P* \< 0.001); AG+GG vs. AA: OR 1.203, 95% CI 1.054--1.373 (*P* = 0.006); GG vs. AA+AG: OR 1.352, 95% CI 1.205--1.516 (*P* \< 0.001); G vs. A: OR 1.184, 95% CI 1.066--1.316 (*P* = 0.002)\]. The results of subgroup analyses based on genotyping methods indicated that rs2274223 polymorphism might increase tumor risk in all genetic models in TaqMan subgroup. In addition, the rs2274223 polymorphism was related to a significantly higher risk of tumor in three genetic models in the PCR subgroup \[AG vs. AA: OR 1.278, 95% CI 1.163--1.405 (*P* \< 0.001); AG+GG vs. AA: OR 1.290, 95% CI 1.178--1.412 (*P* \< 0.001); G vs. A: OR 1.183, 95% CI 1.041--1.344 (*P* = 0.010)\]. However, the rs2274223 polymorphism was associated with tumor risk in a few genetic models in MassArray subgroup and other subgroup. Out of the 35 qualified case-control studies, only one study did not satisfy the HWE. After removing this study, the statistically significant association between rs2274223 polymorphism and cancer risk still existed \[AG vs. AA: OR 1.169, 95% CI 1.083--1.262 (*P* \< 0.001); GG vs. AA: OR 1.341, 95% CI 1.158--1.554 (*P* \< 0.001); AG+GG vs. AA: OR 1.190, 95% CI 1.098--1.288 (*P* \< 0.001); GG vs. AA+AG: OR 1.254, 95% CI 1.098--1.432 (*P* = 0.001); G vs. A: OR 1.157, 95% CI 1.083--1.236 (*P* \< 0.001)\].

###### 

Meta-analysis of the relationship between *PLCE1* rs2274223 polymorphism and cancer risk.

  **SNP**                 ***n***        **Association results**   **Heterogeneity**                                 
  ----------------------- -------------- ------------------------- ---------------------- --------- --------- ------ ---
  **rs2274223**                                                                                                      
  Total                   AG vs. AA      35                        1.168 (1.084, 1.259)   \<0.001   \<0.001   56.4   R
                          GG vs. AA      35                        1.351 (1.163, 1.570)   \<0.001   \<0.001   58.5   R
                          AG+GG vs. AA   35                        1.193 (1.103, 1.290)   \<0.001   \<0.001   63.8   R
                          GG vs. AA+AG   35                        1.262 (1.102, 1.446)   0.001     \<0.001   53.3   R
                          G vs. A        35                        1.163 (1.089, 1.242)   \<0.001   \<0.001   68.3   R
  **CANCER TYPE**                                                                                                    
  GC                      AG vs. AA      10                        1.138 (0.979, 1.323)   0.093     \<0.001   73.0   R
                          GG vs. AA      10                        1.317 (1.041, 1.667)   0.022     0.012     57.3   R
                          AG+GG vs. AA   10                        1.163 (1.002, 1.350)   0.047     \<0.001   74.8   R
                          GG vs. AA+AG   10                        1.271 (1.114, 1.449)   \<0.001   0.037     49.6   F
                          G vs. A        10                        1.144 (1.018, 1.286)   0.023     \<0.001   74.1   R
  EC                      AG vs. AA      17                        1.247 (1.157, 1.344)   \<0.001   0.067     36.4   F
                          GG vs. AA      17                        1.542 (1.247, 1.907)   \<0.001   0.008     51.0   R
                          AG+GG vs. AA   17                        1.266 (1.133, 1.415)   \<0.001   0.004     54.1   R
                          GG vs. AA+AG   17                        1.356 (1.192, 1.544)   \<0.001   0.043     40.5   F
                          G vs. A        17                        1.226 (1.112, 1.351)   \<0.001   \<0.001   63.6   R
  CRC                     AG vs. AA      4                         1.152 (0.963, 1.379)   0.121     0.161     41.8   F
                          GG vs. AA      4                         1.079 (0.406, 2.868)   0.879     0.002     79.4   R
                          AG+GG vs. AA   4                         1.118 (0.818, 1.528)   0.483     0.024     68.2   R
                          GG vs. AA+AG   4                         1.007 (0.412, 2.459)   0.988     0.005     76.6   R
                          G vs. A        4                         1.095 (0.786, 1.525)   0.590     0.001     81.2   R
  HNC                     AG vs. AA      2                         1.091 (0.947, 1.257)   0.225     0.544     0.0    F
                          GG vs. AA      2                         1.289 (0.839, 1.981)   0.246     0.136     55.0   R
                          AG+GG vs. AA   2                         1.111 (0.971, 1.271)   0.127     0.875     0.0    F
                          GG vs. AA+AG   2                         1.251 (0.773, 2.025)   0.362     0.091     65.0   R
                          G vs. A        2                         1.092 (0.983, 1.213)   0.100     0.580     0.0    F
  **ETHNICITY**                                                                                                      
  Asian                   AG vs. AA      21                        1.221 (1.102, 1.352)   \<0.001   \<0.001   67.8   R
                          GG vs. AA      21                        1.665 (1.381, 2.006)   \<0.001   0.001     56.1   R
                          AG+GG vs. AA   21                        1.270 (1.142, 1.412)   \<0.001   \<0.001   72.8   R
                          GG vs. AA+AG   21                        1.465 (1.316, 1.632)   \<0.001   0.016     44.2   F
                          G vs. A        21                        1.251 (1.145, 1.366)   \<0.001   \<0.001   74.0   R
  Caucasian               AG vs. AA      12                        1.078 (0.979, 1.187)   0.128     0.373     7.4    F
                          GG vs. AA      12                        0.991 (0.840, 1.169)   0.913     0.312     13.6   F
                          AG+GG vs. AA   12                        1.066 (0.972, 1.169)   0.177     0.401     4.5    F
                          GG vs. AA+AG   12                        0.955 (0.816, 1.117)   0.561     0.230     21.7   F
                          G vs. A        12                        1.027 (0.958, 1.101)   0.448     0.437     0.7    F
  **SOURCE OF CONTROL**                                                                                              
  HB                      AG vs. AA      19                        1.188 (1.106, 1.277)   \<0.001   0.112     29.4   F
                          GG vs. AA      19                        1.289 (1.009, 1.647)   0.042     \<0.001   60.4   R
                          AG+GG vs. AA   19                        1.206 (1.126, 1.291)   \<0.001   0.018     45.1   F
                          GG vs. AA+AG   19                        1.199 (0.951, 1.512)   0.126     0.001     59.0   R
                          G vs. A        19                        1.150 (1.050, 1.259)   0.003     \<0.001   59.6   R
  PB                      AG vs. AA      15                        1.169 (1.028, 1.329)   0.017     \<0.001   73.0   R
                          GG vs. AA      15                        1.448 (1.184, 1.770)   \<0.001   0.003     58.0   R
                          AG+GG vs. AA   15                        1.203 (1.054, 1.373)   0.006     \<0.001   76.9   R
                          GG vs. AA+AG   15                        1.352 (1.205, 1.516)   \<0.001   0.039     43.1   F
                          G vs. A        15                        1.184 (1.066, 1.316)   0.002     \<0.001   77.1   R
  **GENOTYPING METHOD**                                                                                              
  TaqMan                  AG vs. AA      15                        1.219 (1.144, 1.298)   \<0.001   0.063     38.7   F
                          GG vs. AA      15                        1.369 (1.220, 1.537)   \<0.001   0.048     41.3   F
                          AG+GG vs. AA   15                        1.248 (1.175, 1.325)   \<0.001   0.016     49.1   F
                          GG vs. AA+AG   15                        1.256 (1.125, 1.401)   \<0.001   0.108     32.5   F
                          G vs. A        15                        1.169 (1.082, 1.264)   \<0.001   0.003     57.0   R
  PCR                     AG vs. AA      11                        1.278 (1.163, 1.405)   \<0.001   0.222     23.2   F
                          GG vs. AA      11                        1.196 (0.846, 1.692)   0.311     0.001     66.9   R
                          AG+GG vs. AA   11                        1.290 (1.178, 1.412)   \<0.001   0.040     47.5   F
                          GG vs. AA+AG   11                        1.089 (0.788, 1.505)   0.606     0.002     64.4   R
                          G vs. A        11                        1.183 (1.041, 1.344)   0.010     0.001     66.0   R
  MassArray               AG vs. AA      4                         1.260 (1.065, 1.491)   0.007     0.255     26.0   F
                          GG vs. AA      4                         1.456 (0.626, 3.384)   0.383     0.002     79.9   R
                          AG+GG vs. AA   4                         1.270 (0.955, 1.688)   0.101     0.027     67.3   R
                          GG vs. AA+AG   4                         1.343 (0.617, 2.922)   0.458     0.005     77.0   R
                          G vs. A        4                         1.219 (0.902, 1.648)   0.197     0.002     80.3   R
  Other                   AG vs. AA      5                         0.892 (0.801, 0.993)   0.036     0.105     47.7   F
                          GG vs. AA      5                         1.607 (0.929, 2.777)   0.090     0.034     61.5   R
                          AG+GG vs. AA   5                         0.979 (0.768, 1.249)   0.866     0.031     62.3   R
                          GG vs. AA+AG   5                         1.633 (1.006, 2.651)   0.047     0.074     53.2   R
                          G vs. A        5                         1.063 (0.851, 1.328)   0.591     0.010     70.1   R
  **HWE**                                                                                                            
  *P* \> 0.05             AG vs. AA      34                        1.169 (1.083, 1.262)   \<0.001   \<0.001   57.6   R
                          GG vs. AA      34                        1.341 (1.158, 1.554)   \<0.001   \<0.001   57.6   R
                          AG+GG vs. AA   34                        1.190 (1.098, 1.288)   \<0.001   \<0.001   64.8   R
                          GG vs. AA+AG   34                        1.254 (1.098, 1.432)   0.001     \<0.001   51.8   R
                          G vs. A        34                        1.157 (1.083, 1.236)   \<0.001   \<0.001   68.6   R

*The results were calculated according to random model if I^2^ \> 50%. GC, Gastric cancer; HNC, Head and neck cancer; CRC, Colorectal cancer; EC, Esophageal cancer; HB, Hospital-based; PB, Population-based; R, Random effect model; F, Fixed effect model*.
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Meta-Analysis of the Association Between *PLCE1* rs3765524 Polymorphism and Cancer Susceptibility
-------------------------------------------------------------------------------------------------

There were eight qualified case-control studies in this meta-analysis, which assessed the relationship between the *PLCE1* rs3765524 polymorphism and cancer susceptibility. The results of meta-analysis on the relationship between the *PLCE1* rs3765524 polymorphism and cancer risk are summarized in Table [3](#T3){ref-type="table"} and Figure [3](#F3){ref-type="fig"}. The association between the rs3765524 polymorphism and overall cancer risk was identified in one genetic model \[CT vs. CC: OR 0.681, 95% CI 0.523--0.886 (*P* = 0.004)\]. The results of subgroup analyses are shown in Table [3](#T3){ref-type="table"}. The results of subgroup analyses based on cancer type showed that the rs3765524 polymorphism was associated with risk of esophageal cancer in two genetic models \[CT vs. CC: OR 0.611, 95% CI 0.515--0.726 (*P* \< 0.001); T vs. C: OR 1.154, 95% CI 1.014--1.313 (*P* = 0.029)\]. In addition, the rs3765524 polymorphism was associated with colorectal cancer susceptibility in the specific genetic models \[TT vs. CC: OR 0.431, 95% CI 0.229--0.811 (*P* = 0.009); TT vs. CT+CC: OR 0.429, 95% CI 0.232--0.794 (*P* = 0.007)\]. However, the observed relationship between rs3765524 polymorphism and risk of gastric cancer was not statistically significant. Subgroup analyses according to ethnicity identified an association between the rs3765524 polymorphism and cancer risk in Asians \[CT vs. CC: OR 0.579, 95% CI 0.492--0.680 (*P* \< 0.001)\]. However, the association was not statistically significant in the Caucasian population. The results of stratified analyses based on the source of controls showed that the CT genotype of rs3765524 decreased cancer susceptibility in the population-based subgroup relative to CC genotype \[CT vs. CC: OR 0.568, 95% CI 0.371--0.870 (*P* = 0.009)\]. However, the results of stratified analyses were not statistically significant in the hospital-based subgroup. The results of subgroup analyses based on genotyping method indicated that the rs3765524 polymorphism is not associated with tumor risk in each subgroup. Finally, we carried out subgroup analyses based on HWE. In the subgroup whose genotype frequencies among controls was consistent with HWE, the rs3765524 polymorphism was associated with cancer risk in only one genetic model \[CT vs. CC: OR 0.594, 95% CI 0.511--0.691 (*P* \< 0.001)\]. However, the results were not statistically significant in the subgroup whose genotype frequencies among controls were not consistent with HWE.

###### 

Meta-analysis of the association between *PLCE1* rs3765524 polymorphism and cancer susceptibility.

  **SNP**                 ***n***        **Association results**   **Heterogeneity**                                 
  ----------------------- -------------- ------------------------- ---------------------- --------- --------- ------ ---
  **rs3765524**                                                                                                      
  Total                   CT vs. CC      8                         0.681 (0.523, 0.886)   0.004     0.001     71.5   R
                          TT vs. CC      8                         1.006 (0.766, 1.322)   0.965     0.183     30.6   F
                          CT+TT vs. CC   8                         1.103 (0.974, 1.249)   0.121     0.427     0.3    F
                          TT vs. CT+CC   8                         0.949 (0.726, 1.240)   0.701     0.207     27.7   F
                          T vs. C        8                         1.072 (0.968, 1.186)   0.180     0.215     26.7   F
  **CANCER TYPE**                                                                                                    
  GC                      CT vs. CC      2                         0.677 (0.458, 0.999)   0.050     0.686     0.0    F
                          TT vs. CC      2                         1.127 (0.644, 1.972)   0.676     0.788     0.0    F
                          CT+TT vs. CC   2                         1.283 (0.923, 1.781)   0.138     0.355     0.0    F
                          TT vs. CT+CC   2                         0.994 (0.576, 1.716)   0.983     0.594     0.0    F
                          T vs. C        2                         1.176 (0.906, 1.526)   0.223     0.677     0.0    F
  EC                      CT vs. CC      4                         0.611 (0.515, 0.726)   \<0.001   0.164     41.3   F
                          TT vs. CC      4                         1.334 (0.920, 1.936)   0.129     0.981     0.0    F
                          CT+TT vs. CC   4                         1.149 (0.984, 1.342)   0.079     0.725     0.0    F
                          TT vs. CT+CC   4                         1.277 (0.885, 1.843)   0.191     0.995     0.0    F
                          T vs. C        4                         1.154 (1.014, 1.313)   0.029     0.937     0.0    F
  CRC                     CT vs. CC      2                         0.449 (0.300, 0.672)   0.707     \<0.001   93.9   R
                          TT vs. CC      2                         0.431 (0.229, 0.811)   0.009     0.271     17.5   F
                          CT+TT vs. CC   2                         0.885 (0.678, 1.156)   0.372     0.274     16.4   F
                          TT vs. CT+CC   2                         0.429 (0.232, 0.794)   0.007     0.337     0.0    F
                          T vs. C        2                         0.829 (0.672, 1.024)   0.082     0.204     38.1   F
  **ETHNICITY**                                                                                                      
  Asian                   CT vs. CC      6                         0.579 (0.492, 0.680)   \<0.001   0.221     28.5   F
                          TT vs. CC      6                         1.064 (0.780, 1.451)   0.694     0.146     39.0   F
                          CT+TT vs. CC   6                         1.139 (0.987, 1.314)   0.075     0.289     19.1   F
                          TT vs. CT+CC   6                         0.998 (0.735, 1.355)   0.990     0.185     33.5   F
                          T vs. C        6                         1.095 (0.972, 1.233)   0.135     0.123     42.4   F
  Caucasian               CT vs. CC      2                         0.980 (0.469, 2.047)   0.956     0.005     87.4   R
                          TT vs. CC      2                         0.831 (0.468, 1.477)   0.529     0.272     17.1   F
                          CT+TT vs. CC   2                         1.001 (0.780, 1.285)   0.993     0.796     0.0    F
                          TT vs. CT+CC   2                         0.804 (0.460, 1.404)   0.442     0.204     38.0   F
                          T vs. C        2                         1.012 (0.834, 1.229)   0.901     0.524     0.0    F
  **SOURCE OF CONTROL**                                                                                              
  HB                      CT vs. CC      5                         0.745 (0.515, 1.079)   0.119     0.002     76.6   R
                          TT vs. CC      5                         0.845 (0.490, 1.458)   0.545     0.088     50.6   R
                          CT+TT vs. CC   5                         1.000 (0.848, 1.179)   1.000     0.517     0.0    F
                          TT vs. CT+CC   5                         0.822 (0.573, 1.180)   0.288     0.096     49.3   F
                          T vs. C        5                         0.993 (0.870, 1.133)   0.914     0.168     38.0   F
  PB                      CT vs. CC      2                         0.568 (0.371, 0.870)   0.009     0.081     67.1   R
                          TT vs. CC      2                         1.382 (0.829, 2.303)   0.215     0.913     0.0    F
                          CT+TT vs. CC   2                         1.211 (0.984, 1.490)   0.071     0.992     0.0    F
                          TT vs. CT+CC   2                         1.303 (0.787, 2.158)   0.303     0.929     0.0    F
                          T vs. C        2                         1.185 (0.994, 1.412)   0.059     1.000     0.0    F
  **GENOTYPING METHOD**                                                                                              
  PCR                     CT vs. CC      4                         1.098 (0.925, 1.304)   0.285     0.778     0.0    F
                          TT vs. CC      4                         1.051 (0.705, 1.566)   0.808     0.488     0.0    F
                          CT+TT vs. CC   4                         1.099 (0.931, 1.298)   0.266     0.759     0.0    F
                          TT vs. CT+CC   4                         1.006 (0.680, 1.487)   0.977     0.422     0.0    F
                          T vs. C        4                         1.088 (0.950, 1.246)   0.225     0.678     0.0    F
  MassArray               CT vs. CC      2                         1.022 (0.788, 1.325)   0.869     0.275     16.1   F
                          TT vs. CC      2                         0.662 (0.141, 3.115)   0.601     0.012     84.0   R
                          CT+TT vs. CC   2                         0.968 (0.627, 1.493)   0.882     0.083     66.8   R
                          TT vs. CT+CC   2                         0.657 (0.155, 2.784)   0.568     0.018     82.0   R
                          T vs. C        2                         0.923 (0.568, 1.500)   0.747     0.020     81.6   R
  Other                   CT vs. CC      2                         1.348 (0.994, 1.828)   0.055     0.236     28.8   F
                          TT vs. CC      2                         1.215 (0.729, 2.026)   0.455     0.579     0.0    F
                          CT+TT vs. CC   2                         1.310 (0.987, 1.740)   0.062     0.482     0.0    F
                          TT vs. CT+CC   2                         1.070 (0.650, 1.764)   0.789     0.431     0.0    F
                          T vs. C        2                         1.206 (0.961, 1.513)   0.105     0.850     0.0    F
  **HWE**                                                                                                            
  *P* \> 0.05             CT vs. CC      6                         0.594 (0.511, 0.691)   \<0.001   0.177     34.5   F
                          TT vs. CC      6                         1.076 (0.782, 1.481)   0.652     0.146     38.9   F
                          CT+TT vs. CC   6                         1.081 (0.943, 1.239)   0.263     0.390     4.1    F
                          TT vs. CT+CC   6                         1.048 (0.765, 1.435)   0.772     0.197     31.8   F
                          T vs. C        6                         1.077 (0.962, 1.206)   0.200     0.146     38.9   F
  *P* \< 0.05             CT vs. CC      2                         0.970 (0.424, 2.221)   0.943     0.021     81.3   R
                          TT vs. CC      2                         0.839 (0.496, 1.419)   0.513     0.295     9.0    F
                          CT+TT vs. CC   2                         1.215 (0.901, 1.639)   0.202     0.248     25.1   F
                          TT vs. CT+CC   2                         0.734 (0.441, 1.220)   0.232     0.382     0.0    F
                          T vs. C        2                         1.051 (0.839, 1.317)   0.664     0.249     24.6   F

*The results were calculated according to random model if I^2^ \> 50%. GC, Gastric cancer; CRC, Colorectal cancer; EC, Esophageal cancer; HB, Hospital-based; PB, Population-based; R, Random effect model; F, Fixed effect model*.
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Meta-Analysis of the Relationship Between the *PLCE1* rs753724, rs11187842, and rs7922612 Polymorphisms and Cancer Risk
-----------------------------------------------------------------------------------------------------------------------

The rs753724, rs11187842, and rs7922612 polymorphisms were involved in four, four, and three case-control studies, respectively. The results of meta-analysis on the association between *PLCE1* (rs753724, rs11187842, and rs7922612) polymorphisms and cancer risk are summarized in Table [4](#T4){ref-type="table"} and Figure [S1](#SM1){ref-type="supplementary-material"}. Results indicated no significant relationship between the *PLCE1* rs753724, rs11187842, and rs7922612 polymorphisms and cancer risk. In addition, further subgroup analysis did not identify statistically significant relationships in any genetic model.

###### 

Meta-analysis of the relationship between *PLCE1* rs753724, rs11187842, rs7922612 polymorphisms and cancer risk.

  **SNP**           ***n***        **Association results**   **Heterogeneity**                             
  ----------------- -------------- ------------------------- ---------------------- ------- ------- ------ ---
  **rs753724**                                                                                             
  Total             GT vs. GG      4                         1.371 (0.992, 1.893)   0.056   0.036   65.0   R
                    TT vs. GG      4                         1.088 (0.382, 3.098)   0.875   0.019   69.8   R
                    GT+TT vs. GG   4                         1.354 (0.955, 1.920)   0.089   0.013   72.2   R
                    TT vs. GT+GG   4                         1.008 (0.367, 2.769)   0.987   0.025   67.8   R
                    T vs. G        4                         1.273 (0.911, 1.780)   0.158   0.005   76.7   R
  **CANCER TYPE**                                                                                          
  CRC               GT vs. GG      2                         1.090 (0.830, 1.432)   0.536   0.232   30.0   F
                    TT vs. GG      2                         1.153 (0.204, 6.529)   0.872   0.010   85.0   R
                    GT+TT vs. GG   2                         1.104 (0.664, 1.834)   0.704   0.051   73.8   R
                    TT vs. GT+GG   2                         1.136 (0.217, 5.946)   0.880   0.013   83.7   R
                    T vs. G        2                         1.103 (0.604, 2.014)   0.750   0.008   85.8   R
  **rs11187842**                                                                                           
  Total             CT vs. CC      4                         1.177 (0.867, 1.598)   0.295   0.069   57.7   R
                    TT vs. CC      4                         1.066 (0.361, 3.144)   0.908   0.023   68.6   R
                    CT+TT vs. CC   4                         1.184 (0.894, 1.568)   0.239   0.089   54.0   R
                    TT vs. CT+CC   4                         1.033 (0.345, 3.093)   0.953   0.020   69.6   R
                    T vs. C        4                         1.157 (0.889, 1.506)   0.279   0.061   59.2   R
  **CANCER TYPE**                                                                                          
  CRC               CT vs. CC      2                         0.894 (0.669, 1.195)   0.448   0.956   0.0    F
                    TT vs. CC      2                         1.165 (0.199, 6.820)   0.866   0.010   84.8   R
                    CT+TT vs. CC   2                         0.944 (0.719, 1.240)   0.678   0.378   0.0    F
                    TT vs. CT+CC   2                         1.195 (0.205, 6.980)   0.843   0.010   84.9   R
                    T vs. C        2                         0.996 (0.651, 1.523)   0.984   0.073   68.8   R
  **rs7922612**                                                                                            
  Total             CT vs. CC      3                         0.862 (0.675, 1.100)   0.232   0.498   0.0    F
                    TT vs. CC      3                         0.866 (0.493, 1.520)   0.615   0.088   58.9   R
                    CT+TT vs. CC   3                         0.867 (0.687, 1.093)   0.228   0.244   29.0   F
                    TT vs. CT+CC   3                         0.863 (0.656, 1.134)   0.290   0.185   40.8   F
                    T vs. C        3                         0.901 (0.775, 1.049)   0.179   0.145   48.1   F
  **ETHNICITY**                                                                                            
  Caucasian         CT vs. CC      2                         0.809 (0.612, 1.070)   0.137   0.453   0.0    F
                    TT vs. CC      2                         0.733 (0.371, 1.448)   0.371   0.088   65.7   R
                    CT+TT vs. CC   2                         0.800 (0.612, 1.046)   0.103   0.227   31.4   F
                    TT vs. CT+CC   2                         0.807 (0.601, 1.083)   0.153   0.165   48.2   F
                    T vs. C        2                         0.855 (0.723, 1.011)   0.067   0.185   43.1   F

*The results were calculated according to random model if I^2^ \> 50%. CRC, Colorectal cancer; HB, Hospital-based; PB, Population-base; R, Random effect model; F, Fixed effect model*.

Heterogeneity, Sensitivity Analysis, and Publication Bias
---------------------------------------------------------

Substantial heterogeneities were identified in our meta-analysis. For example, we observed significant heterogeneity in the overall analysis for rs2274223 (*I*^2^ \> 50%). Therefore, we conducted meta-regression analyses to investigate the source of heterogeneity for rs2274223. Results suggested that ethnicity is the likely source of heterogeneity for rs2274223 in the three genetic models (GG vs. AA: *P* = 0.009; GG vs. AA+AG: *P* = 0.009; G vs. A: *P* = 0.048). The genotyping method is a possible source of heterogeneity for rs2274223 in one genetic model (AG vs. AA: *P* = 0.020) (Table [S1](#SM1){ref-type="supplementary-material"}). The results of stratified analyses for rs2274223 were basically consistent with results of meta-regression. However, identifying the source of heterogeneity for rs3765524, rs753724, rs11187842, and rs7922612 was difficult based on stratified analyses. Further, results of sensitivity analysis suggested that the results of meta-analysis were not influenced by any single study in all genetic models for all five polymorphisms, which indicated that our analysis was robust and stable (Figure [4](#F4){ref-type="fig"}). Next, publication bias was evaluated by Egger\'s test and funnel plot. (Table [S2](#SM1){ref-type="supplementary-material"} and Figure [S2](#SM1){ref-type="supplementary-material"}). The results of Egger\'s test showed that all *P*-values were \>0.05 and that the funnel plots were relatively symmetrical, indicating no publication bias was detected in the current analysis.
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Discussion {#s4}
==========

Tumor pathogenesis involves both genetic and environmental factors. As the effects of genetic mutations on cancer continued to be revealed, many authors have focused on the associations between SNPs and cancer susceptibility. *PLCE1* is one of the members of the phospholipase C protein family, which can interact with Ras and participate in cellular signal transduction, produce secondary messengers by hydrolyzing phosphatidylinositol-4, 5-bisphosphate, and regulate cell growth, differentiation, apoptosis, and angiogenesis. ([@B49]--[@B53]) The role of *PLCE1* in cancer remains controversial. The studies of Wang et al. ([@B54], [@B55]) demonstrated that *PLCE1* plays a tumor suppressor role in colorectal carcinoma. However, some studies indicated that *PLCE1* acts as an oncogene in numerous cancers, such as non-small cell lung cancer ([@B56]) and head and neck cancer ([@B57]). Recent years have witnessed an increasing number of studies that investigate *PLCE1* polymorphisms and cancer susceptibility. Likewise, several meta-analyses assessed the association between *PLCE1* polymorphisms and cancer risk. However, most of these studies focused on the relationship between *PLCE1* polymorphisms and digestive tract cancer rather than the overall tumor risk.

Our current findings showed that the rs2274223 polymorphism was associated with overall tumor susceptibility in five genetic models, consistent with the results reported by Xue et al. ([@B14]). However, the current results were slightly different from those reported by Umar ([@B58]), in which the rs2274223 polymorphism showed no significant association with overall cancer susceptibility in one specific genetic model (GG vs. AG+AA). Further stratified analysis revealed that the rs2274223 polymorphism was associated with gastric cancer and esophageal cancer susceptibility, but not with other types of cancer. The above findings were consistent with those reported by Umar ([@B58]), but slightly different from the findings of Xue et al. ([@B14]), which suggested that rs2274223 polymorphism was not associated with susceptibility to gastric cancer. The results based on the esophageal cancer subgroup were consistent with the results of Wang et al. ([@B59]) and Guo et al. ([@B60]). Moreover, the results of the stratified analysis indicated that the rs2274223 polymorphism was associated with cancer susceptibility in Asians but not in Caucasians, consistent with the findings of Umar et al. ([@B58]). Results of subgroup analysis according to the source of controls identified a relationship between rs2274223 polymorphism and tumor risk regardless of whether controls were obtained from a hospital or a population and were also consistent with the findings of Umar et al. ([@B58]). For rs3765524, the results of the present meta-analysis showed that the association between the rs3765524 polymorphism and overall cancer risk was identified in only one genetic model (CT vs. CC). The results of stratified analysis indicated that the rs3765524 polymorphism was associated with colorectal cancer and esophageal cancer susceptibility but not with the other types of cancer. The above findings were distinct from those of Mocellin et al. ([@B61]), which identified an association between the rs3765524 polymorphism and gastric cancer susceptibility. Finally, our results of both the total cancer analysis or subgroup analysis indicated that the rs753724, rs11187842, and rs7922612 polymorphisms were not related to tumor risk. The consistencies between the current and previous meta-analyses might be because some of the literatures included in meta-analyses were the same. Meanwhile, the inconsistencies between the current and previous meta-analyses could be attributed to differences in inclusion criteria. For example, the present meta-analysis specifically required that the qualified studies were case-control studies, which was different from the meta-analysis of Mocellin et al. ([@B61]).

Some limitations still existed in the present analysis, though the analysis was performed carefully. First, relatively few qualified studies were included for investigating rs753724, rs11187842, and rs7922612, and some subgroups included in the stratified analysis had low sample sizes, which might have affected statistical results. Second, unified adjustment about confounders could not be carried out in our analysis because the original data were not obtained. Third, ICD-O codes of cancers from qualified studies were not obtained, and differences in cancers included in the studies might lead to biases. Finally, unpublished materials were not obtained, which might have caused publication bias, although publication bias was not detected based on Begg\'s funnel plots and Egger\'s test in this meta-analysis.

Conclusions {#s5}
===========

Our findings indicated that the *PLCE1* rs2274223 polymorphism is significantly associated with cancer susceptibility in the overall population. On the other hand, the *PLCE1* rs753724, rs11187842, and rs7922612 polymorphisms showed no significant associations with cancer risk. In addition, the results suggested that the *PLCE1* rs3765524 polymorphism is associated with overall cancer risk under the heterozygote model (CT vs. CC).
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